Klor-con and Topicort drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Klor-con (potassium chloride) and Topicort (desoximetasone). Common drug interactions include urticaria among females and colon cancer among males.

The phase IV clinical study analyzes what interactions people have when they take Klor-con and Topicort. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Klor-con?

Klor-con has active ingredients of potassium chloride. It is often used in hypokalemia. eHealthMe is studying from 27,547 Klor-con users. Check the latest studies of Klor-con.

What is Topicort?

Topicort has active ingredients of desoximetasone. eHealthMe is studying from 3,423 Topicort users. Check the latest studies of Topicort.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

16 people who take Klor-con and Topicort together, and have interactions are studied.

Klor-con and Topicort drug interactions.

What are the common drug interactions of Klor-Con and Topicort, by gender? *:

female:

Urticaria (rash of round, red welts on the skin that itch intensely)
Injection site haemorrhage (bleeding from injection site)
Injection site pain
Chronic kidney disease
Death
Eosinophil count increased
Nonspecific reaction (unspecified reaction)
Oral soft tissue disorder (oral soft tissue disease)
Pruritus (severe itching of the skin)
Pyrexia (fever)

male:

Colon cancer
Pancreatic carcinoma (pancreatic cancer)

What are the common drug interactions of Klor-Con and Topicort, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Rash
Skin lesion
Catheter site related reaction
Drug eruption (adverse drug reaction of the skin)
Staphylococcal infection (an infection with staphylococcus bacteria)
Superinfection
Urticaria (rash of round, red welts on the skin that itch intensely)
Eosinophil count increased
Nonspecific reaction (unspecified reaction)
Oral soft tissue disorder (oral soft tissue disease)

30-39:

n/a

40-49:

n/a

50-59:

Nausea (feeling of having an urge to vomit)
Injection site haemorrhage (bleeding from injection site)
Colon cancer
Injection site bruising
Pancreatic carcinoma (pancreatic cancer)
Rash
Injection site pain
Abdominal pain upper
Dizziness
Feeling cold

60+:

Chronic kidney disease
Death
Hyperglycaemia (high blood sugar)
Hypovolaemia (a decreased volume of circulating blood in the body)
Immunodeficiency
Injection site bruising
Injection site discolouration
Injection site pain
Injection site reaction
Injection site warmth

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 31.25%
Pain: 5 people, 31.25%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 25.00%
Constipation: 4 people, 25.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 25.00%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 4 people, 25.00%
Diabetes: 3 people, 18.75%
High Blood Pressure: 3 people, 18.75%
Nausea (feeling of having an urge to vomit): 3 people, 18.75%
Psoriasis (immune-mediated disease that affects the skin): 3 people, 18.75%

* Approximation only. Some reports may have incomplete information.

Do you take Klor-con and Topicort?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously